New research reveals that individuals who discontinue new slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt traditional lifestyle programs.
Published data in a leading health publication shows that while overweight people can lose substantial amounts of their total mass while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying such drugs must be aware of the danger of quick rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a return to original mass within about one and a half years.
Weighing Treatments
The research, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of the injectable medications with older methods.
The team note that people who lose weight through diet and exercise generally experience a less rapid weight regain—approximately 100 grams monthly—once they finish.
Explaining the Fast Regain
Doctors believe the mechanism of the jabs explains the heightened regain.
The injections imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the system to produce less of its endogenous hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in hunger is no longer kept in check, making overeating far more likely."
A Lifelong Condition?
Health authorities recommend the jabs for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts say that, given the high risk of relapse, the therapy might need to be long-term.
This opinion is reinforced by drug manufacturers, who state that the findings "emphasize the long-term nature of obesity," similar to managing diseases like diabetes.
Patient Accounts
Users who have stopped the jabs explain a sudden resurgence of appetite.
"It was like a switch flipping and you become starving," recalled a patient.
This challenge is worsened if individuals have not established sustainable lifestyle or habit modifications during treatment.
Growing Adoption
Recent estimates indicate that a significant number of adults in the UK have tried these injections in the past year, with interest being substantial.
- Adoption is more common among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
Ultimately, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent cure and maintained weight loss hinges on ongoing lifestyle changes.
